Three phase 2 trials have already been completed, and the published results demonstrate that insulin Efsitora alfa is effective and safe in patients with T1D [27] when compared to once-daily insulin Degludec U100 and both T2D insulin-naïve [28] and insulin users [29]. Here, INS is linked to type 1 diabetes mellitus.